What is SS-31?
A synthetic tetrapeptide that selectively targets the inner mitochondrial membrane — concentrating within mitochondria up to 5,000-fold over cytoplasmic levels to restore electron transport chain function and reduce oxidative stress at the source.
SS-31, also known as elamipretide (INN), is a synthetic tetrapeptide with the sequence D-Arg–2′,6′-dimethyltyrosine–Lys–Phe-NH₂ (D-Arg-Dmt-Lys-Phe-NH₂). It is a cell-permeable, mitochondria-targeted compound engineered to accumulate selectively within the inner mitochondrial membrane — achieving mitochondrial concentrations estimated at 1,000 to 5,000 times the cytoplasmic level. This extraordinary selectivity arises from its electrostatic interaction with cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane and essential to the structural and functional integrity of the electron transport chain.
Unlike broad-spectrum antioxidants that scavenge reactive oxygen species (ROS) after their formation, SS-31 is positioned at the mitochondrial source of oxidative stress. Its molecular design enables it to intercalate into the inner membrane and interact directly with the lipid environment surrounding the respiratory complexes, addressing mitochondrial dysfunction at its origin rather than at its downstream consequences. This distinction is central to SS-31's relevance in cellular energy and ageing research.
Mechanism of Action
How SS-31 Works
SS-31's primary mechanism centres on its high-affinity binding to cardiolipin, a diphospholipid that constitutes approximately 15–20% of the inner mitochondrial membrane's lipid composition. Cardiolipin is indispensable for the organisation and activity of the electron transport chain (ETC): it serves as a structural scaffold for Complexes III and IV, facilitates electron transfer between complexes, and maintains the proton gradient required for ATP synthesis. Under conditions of oxidative stress, cardiolipin undergoes peroxidation, destabilising the ETC and perpetuating a cycle of electron leakage and ROS generation.
By binding to cardiolipin, SS-31 stabilises the quaternary structure of Complex III (cytochrome bc₁) and Complex IV (cytochrome c oxidase), restoring efficient electron flow through the chain. This reduces electron leakage at Complexes I and III — the primary sites of mitochondrial superoxide production — and consequently lowers the generation of reactive oxygen species. The net effect is improved ATP synthesis efficiency with a concomitant reduction in oxidative stress.
SS-31 also normalises the mitochondrial membrane potential (ΔΨm). In dysfunctional mitochondria, membrane potential becomes hyperpolarised or depolarised, both of which promote electron slippage and ROS formation. By restoring the coupling efficiency between electron transport and ATP production, SS-31 brings ΔΨm closer to physiological range. Additionally, SS-31 has been shown to protect against opening of the mitochondrial permeability transition pore (mPTP) — a non-selective channel whose opening triggers cytochrome c release and initiates the intrinsic apoptotic cascade. Inhibition of mPTP opening is relevant to research on cellular repair and tissue preservation in ischaemic and degenerative models.
Mitochondrial Dysfunction Research
Preclinical and Disease-Model Studies
Mitochondrial decline is now recognised as a hallmark of biological ageing. As organisms age, mitochondrial DNA accumulates mutations, respiratory chain efficiency deteriorates, and ROS production increases — a self-amplifying process that contributes to cellular senescence, tissue dysfunction, and organ-level degeneration. SS-31 has been investigated in a range of preclinical models in which mitochondrial dysfunction is a central pathogenic factor.
In models of cardiac ischaemia-reperfusion injury, SS-31 has been observed to reduce infarct size and preserve cardiac output by maintaining mitochondrial membrane integrity during the oxidative surge that follows reperfusion. In the kidney, SS-31 has been studied in models of renal fibrosis, where mitochondrial dysfunction drives tubular cell death and interstitial scarring. Research in the central nervous system has explored SS-31's effects in transgenic models of Alzheimer's disease and Parkinson's disease, where mitochondrial impairment is implicated in neuronal loss and protein aggregation.
In skeletal muscle, SS-31 has been examined in the context of sarcopenia — the age-related loss of muscle mass and function — with studies indicating improvements in mitochondrial respiratory capacity and muscle fatigue resistance. Research in ophthalmology has investigated SS-31 in models of macular degeneration, where retinal pigment epithelial cells are particularly vulnerable to mitochondrial oxidative damage due to high metabolic demand and chronic light exposure.
Ageing and Cellular Energy
The Mitochondrial Free Radical Theory
The mitochondrial free radical theory of ageing, first proposed by Denham Harman in 1972 and refined substantially since, posits that the accumulation of oxidative damage to mitochondrial DNA, lipids, and proteins — driven by endogenous ROS production from the electron transport chain — is a primary driver of age-related physiological decline. As mitochondria become progressively damaged, they produce more ROS while generating less ATP, creating a deteriorative feedback loop that accelerates cellular ageing.
SS-31's mechanism is distinct from conventional antioxidant strategies. Rather than scavenging reactive oxygen species after they have formed — an approach that has yielded largely disappointing results in ageing research — SS-31 addresses the upstream cause: dysfunctional electron transport within the mitochondria themselves. By stabilising the respiratory complexes and improving the coupling efficiency of oxidative phosphorylation, SS-31 reduces ROS generation at its source while simultaneously enhancing cellular energy production.
This positions SS-31 as a research tool for investigating whether restoring mitochondrial function can reverse — rather than merely slow — age-related cellular decline. The distinction is significant: if mitochondrial dysfunction is a causative factor in ageing rather than a passive consequence, then normalising mitochondrial bioenergetics may have systemic implications for tissue function, organ resilience, and organismal longevity. These questions remain the subject of active preclinical and translational investigation, and no clinical claims are implied.
All products are research compounds intended for laboratory research use only. Not for human or veterinary use. Kinetic Labs does not provide dosing guidance, therapeutic recommendations, or medical advice of any kind.